Tous Actualités
Suivre
Abonner Eisai Europe Limited

Eisai Europe Limited

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

London (ots/PRNewswire)

Eisai Europe Ltd announced today
that results from 9 clinical data abstracts about compounds in the
company's oncology pipeline, product portfolio and preclinical
oncology research have been accepted for presentation at the 44th
Annual Meeting of the American Society of Clinical Oncology (ASCO),
taking place in Chicago from May 30 to June 3, 2008.
A wide variety of abstracts on Eisai investigational compounds
will showcase research focused on metastatic breast cancer, lung
cancer, ovarian cancer, mesothelioma, pancreatic cancer and other
types of cancer, as well as supportive care to aid those currently
undergoing treatment for cancer.
"Eisai's commitment to oncology is clearly translating into the
substantial growth of our pipeline," said Haruo Naito, President and
CEO, Eisai Co., Ltd. "Eisai's focus on becoming a global leader in
oncology reflects our human health care mission to satisfy unmet
medical needs and increase benefits to patients and their families."
The following Eisai abstracts are accepted for presentation at
this year's ASCO meeting.
    Product         Abstract Details                             Location
                                                                 Details
    MORAb-003       Exploratory Phase II Efficacy Study of       June 1, 2008
                    MORAb-003, a Monoclonal Antibody against
    (farletuzumab)  Folate Receptor Alpha, in                    4:30-4:45
                    Platinum-Sensitive Ovarian Cancer in First   p.m.
    Abstract No:    Relapse
    5500                                                         Location:
                    Oral Presentation                            S406 (Vista
                                                                 Room)
    E7080           A phase I study of E7080 in patients with    May 31, 2008
                    advanced malignancies
    Abstract No:                                                 8:00
    3526                                                         a.m.-12:00
                                                                 p.m.
                    Poster 3
                                                                 Location:
                    Awarded a Foundation Merit Award             W375E Lobby
                                                                 Poster
                                                                 discussion
                                                                 12:00-1:00
                                                                 p.m.
                                                                 Location:
                                                                 W375A
    E7080           Phase I dose escalation study and biomarker  May 31, 2008
                    analysis of E7080 in patients with advanced
    Abstract No:    solid tumors                                 8:00
    3527                                                         a.m.-12:00
                    Poster 4                                     p.m.
                                                                 Location:
                                                                 W375E Lobby
                                                                 Poster
                                                                 discussion
                                                                 12:00-1:00
                                                                 p.m.
                                                                 Location:
                                                                 W375A
    MORAb-003       A Phase I Study of MORAb-003, a Humanized    May 31, 2008
                    Monoclonal Antibody Against Folate Receptor
    (farletuzumab)  Alpha, in Advanced Epithelial Ovarian        2:00-6:00
                    Cancer                                       p.m.
    Abstract No:
    5517            Poster 7                                     Location:
                                                                 S403
                                                                 Poster
                                                                 discussion
                                                                 5:00-6:00
                                                                 p.m.
                                                                 Location:
                                                                 S406 (Vista
                                                                 Room)
    GCP II          Glutamate Carboxypeptidase II Inhibition in  May 31, 2008
    Inhibitor       Rat Models of Chemotherapy-induced
                    Peripheral Neurotoxicity                     2:00-6:00
    Abstract No:                                                 p.m.
    9558            Poster 37A
                                                                 Location: S
                                                                 Hall A1
    E7820           A phase I study of E7820 in combination      June 1, 2008
                    with cetuximab in patients (pts) with
    Abstract No:    advanced solid tumors                        2:00-6:00
    3568                                                         p.m.
                    Poster 24G
                                                                 Location: S
                                                                 Hall A1
    MORAb-009       A Phase I Study of MORAb-009, a Monoclonal   June 1, 2008
                    Antibody against Mesothelin, in
    Abstract No:    Mesothelioma, Pancreatic, and Ovarian        2:00-6:00
    3578            Cancer                                       p.m.
                    Poster 27C                                   Location: S
                                                                 Hall A1
    Eribulin        Phase II Study of Eribulin                   June 2, 2008
    Mesylate        Mesylate (E7389) in Patients
    (E7389)         with Locally Advanced or                     2:00-6:00
                                                                 p.m.
    Abstract No:    Metastatic Breast Cancer                     Location:
    1084            Previously Treated with                      S Hall A1
                    Anthracycline, Taxane, and
                    Capecitabine Therapy
                    Poster 38A
    Advanced Breast Oncologist and Patient Roles in              June 2,
    Cancer          Assessing Current and Future                 2008
                    Treatment for Metastatic Breast              2:00-6:00
    Abstract No:    Cancer: Results of an                        p.m.
    1064            Observational Linguistic study               Location:
                    Poster 32B                                   S Hall A1
Eisai began its oncology research program in 1987, discovering
several small molecules that are in development as chemotherapeutic
agents. In addition to its in-house oncology research and development
(R&D) program, Eisai made three strategic acquisitions to establish a
solid business infrastructure and enter the oncology market.
In October 2006, Eisai acquired four products mainly for the
treatment of cutaneous T-cell lymphoma, as well as an oncology
specialty sales force from Ligand Pharmaceuticals. This provided
Eisai with an initial commercial infrastructure for oncology
products. The acquisition of Morphotek, Inc. in April 2007 added
important antibody technology and an antibody pipeline. In January
2008, Eisai acquired MGI PHARMA, INC., an oncology and acute
care-focused company, to broaden its R&D and commercial capabilities,
pipeline and product portfolio in oncology and supportive care.
Eisai is committed to addressing the unmet medical needs of
patients with cancer and to delivering novel treatment options that
create hope.
Note to Editors
About Eisai Europe Ltd.
Established in 1989, Eisai Europe Ltd. is the European
pharmaceutical subsidiary of Eisai Co. Ltd., a research-based human
health care (hhc) company that discovers, develops and markets
products throughout the world. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai
actively participates in all aspects of the worldwide health care
system. Eisai focuses its efforts in two main therapeutic areas;
integrative neurology and integrative oncology/critical care. Eisai
employs more than 9,500 people worldwide.

Contact:

For further information please contact: Andrew Day, Communications
Director, Eisai Europe Ltd, +44(0)208-600-1400, +44(0)7973-411-419

Plus de actualités: Eisai Europe Limited
Plus de actualités: Eisai Europe Limited
  • 28.09.2007 – 18:10

    Eisai Announce Application to Appeal NICE Judicial Review Verdict

    London (ots/PRNewswire) - Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, announced today that Eisai has applied to the Court of Appeal for permission to appeal the recent High Court ruling on the process by which the National Institute for Health and Clinical Excellence (NICE) reached its ...

  • 15.06.2007 – 10:40

    Inovelon(R) A New Treatment for Lennox-Gastaut Syndrome Launched in Europe

    London (ots/PRNewswire) - - First Treatment Licensed Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, (Headquarters: London, President Yutaka Tsuchiya) today announced the launch in Germany and Scandinavia of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome ...